Ameliorative effect of Citrus aurantifolia and Cinnamomum burmannii extracts on diabetic complications in a hyperglycemic rat model
Abstract
Purpose: To evaluate the effects of Citrus aurantifolia and <i>Cinnamomum burmannii</i> extracts (Jermanis) on the number of pancreatic β-cells and levels of superoxide dismutase (SOD), low-density lipoprotein
(LDL), and transforming growth factor-beta (TGF-β) in β-cells.
Methods: Various doses of a combination of extracts of <i>C. aurantifolia</i> and </i>C. burmannii </i>were given orally to 25 male Wistar rats (<i>Rattus norvegicus</i>) every 2 h for 30 days. Doses of 100, 300 and 500 mg/kg/day <i>C. aurantifolia</i> extract were considered low, medium and high doses, respectively, while, 200, 400 and 800 mg/kg/day <i>C. burmannii</i> extract were considered low, medium and high doses, respectively. LDL and SOD levels in blood serum were analyzed spectrophotometrically. TGF-β expression was evaluated by immunohistochemistry. Pancreatic tissue sections (diameter of a β-cell) were evaluated by light microscopy after hematoxylin and eosin staining.
Results: The combination of <i>C. aurantifolia</i> and <i>C. burmannii </i>extracts increased SOD levels, TGF-β expression and the number of β-cells and decreased LDL levels in hyperglycemic rats. The results indicate that the highest doses of <i>C. aurantifolia</i> and <i>C. burmannii</i> increased the number of β-cells in the islets of Langerhans. The combined extracts of <i>C. aurantifolia</i> and <i>C. burmannii</i> significantly affected pancreatic cell regeneration.
Conclusion: The combination of <i>C. aurantifolia</i> and <i>C. burmannii</i> extracts may be a promising alternative preventative medicine for management of diabetic complications in patients with hyperglycemia.
Keywords: β-cell, Diabetes, Diabetic complications, C<i>itrus aurantifolia, Cinnamomum burmannii</i>, Biochemical profile, TGF-β expression
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
